FDA approves LivaNova aura6000 for obstructive sleep apnea

LivaNova has secured US FDA premarket approval for the aura6000 System, an implantable hypoglossal nerve stimulation device for adults with moderate to severe obstructive sleep apnea. The decision, recorded by FDA on March 18, 2026, gives the company a PMA-approved foothold in a market that has been closely watched for new options beyond positive airway pressure and oral appliances. (accessdata.fda.gov)

The approval caps a multiyear regulatory path. LivaNova received FDA investigational device exemption approval in June 2021 to begin the OSPREY study in the US, describing aura6000 as an outpatient implanted system that stimulates the hypoglossal nerve to help keep the airway open during sleep. At that point, the company said the device had already received CE mark in 2012, but it still needed confirmatory US data to support a premarket application. (investor.livanova.com)

That confirmatory evidence came from OSPREY, a prospective, multicenter, randomized, controlled, open-label trial in adults with moderate to severe OSA who had failed, declined, or were unwilling to use PAP therapy. LivaNova announced in November 2024 that the study met its primary safety and efficacy endpoints, then said in May 2025 that it had completed the PMA submission. In the 12-month topline update, the company reported a 65% responder rate, defined as at least a 50% improvement from baseline AHI and an AHI below 20, along with 68% median reductions in both AHI and oxygen desaturation index. No serious device-related or procedure-related adverse events were reported in the company’s trial updates. (investor.livanova.com)

FDA’s approval order provides the formal indication: the aura6000 is approved to reduce apneas and hypopneas in adult patients with an AHI of 15 to 65 who have failed, do not tolerate, or are ineligible for standard-of-care treatments including PAP, oral appliances, or pharmacotherapy. The PMA listing also identifies the application as P250013, received April 25, 2025, under product code MNQ. (accessdata.fda.gov)

LivaNova is emphasizing what it sees as a competitive differentiator. In its March 19, 2026 announcement, the company said aura6000 is the first and only US-approved hypoglossal nerve stimulation therapy without complete concentric collapse contraindication or warning language, and without a requirement for pre-implant drug-induced sleep endoscopy. The company also said OSPREY did not exclude patients with complete concentric collapse risk, and that outcomes in those patients were consistent with the broader study population. That framing matters because patient selection has been a practical bottleneck in sleep apnea implant programs. (nasdaq.com)

Outside commentary has focused on the same access and positioning questions. Before approval, Needham analyst Michael Matson said aura6000 could have an edge because it may reach patients excluded by other hypoglossal nerve stimulation systems, avoid a drug-induced sleep endoscopy step, and offer longer battery life. Trade coverage after the decision likewise highlighted the absence of complete concentric collapse warning language as a notable distinction in the US market. (mddionline.com)

The decision also lands in a broader neuromodulation environment that remains active well beyond sleep apnea. In another recent FDA milestone, Nia Therapeutics said its Smart Neurostimulation System received Breakthrough Device Designation for episodic memory loss in adults with prior moderate to severe traumatic brain injury and persistent memory deficits. Nia describes that platform as a fully implantable, closed-loop system that records neural activity from 60 channels across four brain regions and delivers targeted stimulation to the lateral temporal cortex. In a sham-controlled study in neurosurgical patients with epilepsy and a history of TBI, the company said the system improved recall by 19%, while random stimulation showed no benefit; it plans to file an IDE application in 2026. While that program is much earlier-stage and in a different indication, it adds context to the FDA’s continuing engagement with increasingly sophisticated implantable neurostimulation technologies.

Why it matters: For veterinary professionals, this isn’t a companion animal care story, but it is relevant as a window into the broader medtech and regulatory environment. The approval underscores the continued momentum behind implantable neuromodulation, the value FDA is placing on randomized controlled evidence for device approvals, and the commercial push toward less burdensome chronic-disease therapies when first-line treatment adherence is poor. For teams tracking translational technology, it’s another example of neurostimulation moving beyond its earlier cardiovascular and neurologic strongholds into airway and sleep-related disease, even as other developers pursue closed-loop applications in areas such as memory loss after brain injury. (investor.livanova.com)

What to watch: The next milestones are commercial rollout, reimbursement decisions, real-world adoption, and FDA review of LivaNova’s planned PMA supplement for a next-generation version with MRI compatibility, remote configuration management, and a rechargeable battery the company says could last up to 15 years. LivaNova has said that upgraded system is expected in the first half of 2027, pending FDA supplement review. More broadly, the neuromodulation pipeline remains worth watching for additional FDA designations and IDE filings, including Nia’s planned 2026 submission. (nasdaq.com)